|1.||Konstas, Anastasios G P: 10 articles (01/2015 - 03/2006)|
|2.||Bergamini, Michael V W: 10 articles (06/2008 - 08/2002)|
|3.||Stewart, William C: 8 articles (01/2010 - 03/2003)|
|4.||Landry, Theresa A: 7 articles (06/2008 - 07/2005)|
|5.||Holló, Gábor: 6 articles (09/2013 - 12/2005)|
|6.||Denis, Philippe: 6 articles (01/2012 - 01/2006)|
|7.||Kahook, Malik Y: 5 articles (06/2014 - 04/2008)|
|8.||Stewart, Jeanette A: 5 articles (01/2010 - 03/2003)|
|9.||Mallick, Sushanta: 5 articles (06/2008 - 07/2005)|
|10.||Sullivan, E Kenneth: 5 articles (01/2007 - 05/2002)|
|1.||Open-Angle Glaucoma (Glaucoma, Open Angle)
10/01/2014 - "The present study demonstrated the long-term 24-hour efficacy of travoprost for the treatment of primary open-angle glaucoma."
10/01/2014 - "The aim of the study was to evaluate the long-term 24-hour intraocular pressure (IOP) efficacy of travoprost monotherapy in primary open-angle glaucoma patients. "
04/01/2009 - "This study suggests that when both drugs are dosed in the evening the TTFC provides improved intraocular pressure reduction, compared with travoprost, over the 24 h curve and for each individual time point in primary open-angle glaucoma patients."
12/01/2004 - "Effects of travoprost 0.004% ophthalmic solution, six weeks after its laminated packaging had been removed, in primary open-angle glaucoma: a randomized, controlled, investigator-blinded study."
10/01/2014 - "Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma."
|2.||Ocular Hypertension (Glaucoma, Suspect)
02/01/2013 - "Alternate day use of travoprost 0.004% was as safe and effective as its daily use in lowering the IOP in patients with ocular hypertension."
02/01/2013 - "Fourteen patients with ocular hypertension in both eyes have been randomly assigned to receive travoprost 0.004% once a day in 1 eye and once every other day in the other eye. "
02/01/2013 - "To compare the daily versus the alternate day use of travoprost 0.004% in lowering the intraocular pressure (IOP) in patients with ocular hypertension. "
02/01/2013 - "A short-term randomized clinical trial of daily versus alternate day use of travoprost 0.004% in the treatment of ocular hypertension."
05/01/2003 - "Two prospective, controlled, multicenter, double-masked studies--one lasting 6 months (n=594) and the other, 12 months (n=787)--examined the intraocular pressure (IOP)-lowering efficacy of travoprost in 1381 black and nonblack patients with open-angle glaucoma or ocular hypertension. "
01/01/2010 - "The proven efficacy and safety combined with convenient once-daily dosing for travoprost increases patient compliance with treatment for glaucoma."
03/01/2012 - "To evaluate the changes in intraocular pressure (IOP) and pupil size in 12 Beagles with inherited glaucoma after instillations of 0.033, 0.0033, 0.001, 0.00033, and 0.0001% travoprost (Travatan®-Alcon Laboratories, Inc., Ft Worth, TX, USA) in multiple single-dose studies. "
02/01/2009 - "Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study."
01/01/2007 - "The results from this study support the concept that the majority of glaucoma patients, who are responding inadequately to other glaucoma therapies, could benefit from a change to travoprost monotherapy or from the addition of travoprost to their existing therapy."
03/01/2014 - "DUES is a common side effect of topical travoprost treatment in Japanese glaucoma patients."
|4.||Low Tension Glaucoma
01/01/2012 - "BAK-free travoprost monotherapy was effective in reducing intraocular pressure for at least 3 years; however, visual field performance worsened in 2.8%-13.9% of patients with normal tension glaucoma."
01/01/2014 - "This study aimed to evaluate the effect of travoprost with sofZia® preservative system for lowering the intraocular pressure (IOP) of Japanese normal tension glaucoma (NTG) patients. "
08/01/2008 - "The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial."
01/01/2014 - "The diurnal and nocturnal effects of travoprost in normal-tension glaucoma."
01/01/2014 - "Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects."
09/01/2008 - "Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control."
01/01/2012 - "Results of the safety analysis were consistent with the results from the individual studies for travoprost ophthalmic solution 0.004%, with ocular hyperemia being the most common side effect. "
08/01/2015 - "Hyperemia was the most frequent treatment-related adverse event with both formulations (travoprost 0.003%, 11.8%; travoprost 0.004%, 14.5%). "
09/01/2008 - "Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001). "
01/01/2007 - "Adverse events due to hyperemia occurred in 6.4% and 9.0% of patients treated with travoprost 0.004% without BAC and travoprost 0.004% with BAC, respectively. "
|7.||Benzalkonium Compounds (Benzalkonium Chloride)